Analyses of vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens
Author:
Barrett JR, Silk SE, Mkindi CG, Kwiatkowska KM, Hou MMORCID, Lias AM, Kalinga WF, Mtaka IM, McHugh K, Bardelli M, Davies H, King LDW, Edwards NJ, Chauhan VS, Mukherji P, Rwezaula S, Chitnis CE, Olotu AI, Minassian AM, Draper SJORCID, Nielsen CM
Abstract
AbstractWe have previously reported primary endpoints of a clinical trial testing two vaccine platforms for delivery ofPlasmodium vivaxmalaria DBPRII: viral vectors (ChAd63, MVA) and protein/adjuvant (PvDBPII with 50µg Matrix-M™ adjuvant). Delayed boosting was necessitated due to trial halts during the pandemic and provides an opportunity to investigate the impact of dosing regimens. Here, using flow cytometry – including agnostic definition of B cell populations with the clustering tool CITRUS – we report enhanced induction of DBPRII-specific plasma cell and memory B cell responses in protein/adjuvant versus viral vector vaccinees. Within protein/adjuvant groups, delayed boosting further improved B cell immunogenicity as compared to a monthly boosting regimen. Consistent with this, delayed boosting also drove more durable anti-DBPRII serum IgG. In an independent vaccine clinical trial with theP. falciparummalaria RH5.1 protein/adjuvant (50µg Matrix-M™) vaccine candidate, we similarly observed enhanced circulating B cell responses in vaccinees receiving a delayed final booster. Notably, a higher frequency of vaccine-specific (putatively long-lived) plasma cells were detected in the bone marrow of these delayed boosting vaccinees by ELISPOT and correlated strongly with serum IgG.Finally, following controlled human malaria infection withP. vivaxparasites in the DBPRII trial,in vivogrowth inhibition was observed to correlate with DBPRII-specific B cell and serum IgG responses. In contrast, the CD4+ and CD8+ T cell responses were impacted by vaccine platform but not dosing regimen, and did not correlate within vivogrowth inhibition in a challenge model. Taken together, our DBPRII and RH5 data suggest an opportunity for dosing regimen optimisation in the context of rational vaccine development against pathogens where protection is antibody-mediated.
Publisher
Cold Spring Harbor Laboratory
Reference24 articles.
1. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) 2. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials 3. R.P. Payne , S. Longet , J.A. Austin , D.T. Skelly , W. Dejnirattisai , S. Adele , N. Meardon , S. Faustini , S. Al-Taei , S.C. Moore , T. Tipton , L.M. Hering , A. Angyal , R. Brown , A.R. Nicols , N. Gillson , S.L. Dobson , A. Amini , P. Supasa , A. Cross , A. Bridges-Webb , L.S. Reyes , A. Linder , G. Sandhar , J.A. Kilby , J.K. Tyerman , T. Altmann , H. Hornsby , R. Whitham , E. Phillips , T. Malone , A. Hargreaves , A. Shields , A. Saei , S. Foulkes , L. Stafford , S. Johnson , D.G. Wootton , C.P. Conlon , K. Jeffery , P.C. Matthews , J. Frater , A.S. Deeks , A.J. Pollard , A. Brown , S.L. Rowland-Jones , J. Mongkolsapaya , E. Barnes , S. Hopkins , V. Hall , C. Dold , C.J.A. Duncan , A. Richter , M. Carroll , G. Screaton , T.I. de Silva , L. Turtle , P. Klenerman , S. Dunachie , and P. Consortium , Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell (2021). 4. Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination;Med (N Y),2021 5. C.M. Nielsen , J.R. Barrett , C. Davis , J.K. Fallon , C. Goh , A.R. Michell , C. Griffin , A. Kwok , C. Loos , S. Darko , F. Laboune , M. Tekman , A. Diouf , K. Miura , J.R. Francica , A. Ransier , C.A. Long , S.E. Silk , R.O. Payne , A.M. Minassian , D.A. Lauffenburger , R.A. Seder , D.C. Douek , G. Alter , and S.J. Draper , Delayed boosting improves human antigen-specific Ig and B cell responses to the RH5.1/AS01B malaria vaccine. JCI Insight 8 (2023).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|